Protai
Drug Discovery · Bioinformatics
$28Mtotal raised · 2 rounds on record
$20Mlatest round · Seed · Mar 2023 · 3 yr ago
1backers · Grove Ventures
50+team · employees, estimated range
Overview
Protai leverages proteomics and AI to accelerate drug discovery, enabling faster identification of novel therapeutic targets and biomarkers.
Key facts
These are the key facts about Protai on Alion as of Nov 13, 2026. It has raised $28M in 2 funding rounds. The latest round is Seed of $20M, announced in 2023.
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $28MSum of 2 equity rounds Alion knows
- Latest round
- Seed · $20M · Mar 15, 2023Press report · hitconsultant.net
Funding and backers
Total raised
$28M
2 rounds on record
Latest round
$20M
Seed · Mar 2023 · 3 yr ago
Team
51-200
employees, estimated range
Backers
1
Grove Ventures
The money's age
Long since its last round
43 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 15, 2023
Raised a round Seed $20M
Jan 5, 2022
Raised a round Seed $8M · PRNewswire
Dec 2021
Website went live first capture in the Wayback Machine
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | Mar 2023 | $20M | — | hitconsultant.net |
| Seed | Jan 2022 | $8M | — | PRNewswire |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Peptris is an AI-powered preclinical drug discovery company, leveraging cutting-edge technology to accelerate the discovery of novel…
CrystalsFirst reimagines small-molecule drug discovery. The MAGNET platform integrates structural biology and AI accelerating drug…
Turbine is virtualizing biological experiments with AI to accelerate drug discovery and enhance clinical translatability.
Decode ProteinInteractions 10× Faster. Bionsight combines cutting-edge chemoproteomics with artificial intelligence to identify therapeutic…
Endogene.bio generates high-resolution data from menstrual blood to accelerate disease understanding, patient stratification, and…
Westlake Omics offers AI virtual cells, proteomics research services and clinical diagnostic technologies, including IGF-I and ThyroProt.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Grove VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Standigm and Protai Launch Joint R&D Program to Design Selective Molecular Glue Degraders Using Structural Proteomics and Generative AI
Standigm, an AI-driven drug discovery company, and Protai, a proteomics and AI-based drug discovery company, today announced a joint research and development program to build an integrated platform for the discovery of selective molecular glue degraders (
Read more
Report
Standigm and Protai Launch Joint R&D Program to Design Selective Molecular Glue Degraders Using Structural Proteomics and Generative AI
/PRNewswire/ -- Standigm, an AI-driven drug discovery company, and Protai, a proteomics and AI-based drug discovery company, today announced a joint research...
Read more
Report
Standigm and Protai Launch Joint R&D Program to Design Selective Molecular Glue Degraders Using Structural Proteomics and Generative AI
Read more
Report
Protai to showcase groundbreaking AIMS drug discovery platform and best-in-class PRT001 KAT6A degrader results at spring 2026 global conferences.
Protai, www.protai.bio, an AI drug discovery startup, announced its participation in a series of major scientific conferences this spring, where it will present significant advances in its AIMS proteomics-aware-AI drug discovery platform and breakthrough
Read more
Report
Protai to showcase groundbreaking AIMS(TM) drug discovery platform and best-in-class PRT001 KAT6A degrader results at spring 2026 global conferences.
Read more
Report
Protai Raises $20M to Build an Oncology Drug Discovery Pipeline
Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered raises $20M in seed funding.
Read more
Report
Protai Raises $8 Million Seed Round to Provide a Proteomics-based Platform for Faster and More Accurate Drug Discovery
/PRNewswire/ -- Protai, an AI-powered drug discovery startup, today announced its emergence from stealth, along with an $8 million seed financing round co-led...
Read more
Report
How to cite this page
Alion, "Protai: key facts", as of Nov 13, 2026. https://alion.io/company/protai
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0